Piqray (alpelisib)

pCPA File Number: 21749
Negotiation Status:
Concluded without agreement
Indication(s):
In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0247
pCPA Engagement Letter Issued:
Negotiation Process Concluded: